Legend Biotech Corp (LEGN)
45.41
-0.52
(-1.13%)
USD |
NASDAQ |
May 03, 16:00
45.42
0.00 (0.00%)
After-Hours: 20:00
Legend Biotech Cash from Investing (TTM): 92.79M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 92.79M |
September 30, 2023 | -289.79M |
June 30, 2023 | 47.17M |
March 31, 2023 | 173.34M |
December 31, 2022 | -77.09M |
September 30, 2022 | -5.512M |
June 30, 2022 | -239.08M |
March 31, 2022 | -410.33M |
December 31, 2021 | -194.98M |
Date | Value |
---|---|
September 30, 2021 | -230.33M |
June 30, 2021 | -183.28M |
March 31, 2021 | -23.82M |
December 31, 2020 | -24.17M |
September 30, 2020 | 28.12M |
June 30, 2020 | 65.55M |
March 31, 2020 | 38.73M |
December 31, 2019 | -58.65M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-410.33M
Minimum
Mar 2022
173.34M
Maximum
Mar 2023
-75.96M
Average
-24.17M
Median
Dec 2020
Cash from Investing (TTM) Benchmarks
Johnson & Johnson | -2.901B |
Bristol-Myers Squibb Co | -21.70B |
2seventy bio Inc | 43.86M |
Exelixis Inc | 134.43M |
Alnylam Pharmaceuticals Inc | -327.75M |